Healthy
Conditions
Brief summary
The main aim of the present study is to investigate whether intranasal vasopressin (20IU) could influence attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.
Detailed description
A number of previous studies have reported vasopressin's effect on human social behavior and social cognition, although it remains unclear whether vasopressin could modulate attention allocation including stimulus-driven bottom-up control and goal-directed top-down control. In the current randomized, between-subject, placebo controlled study, 89 healthy male subjects will be recruited and receive either vasopressin (20 IU) or placebo control administered intranasally. 45 minutes after treatment subjects will be required to complete a social-emotional saccade /antisaccade eye-tracking paradigm. The paradigm uses social (happy, sad, angry, fear, and neutral faces) as well as non-social (oval shapes) stimuli to explore social- and emotion-specific effects of vasopressin.
Interventions
DRUGVasopressin
Administration of vasopressin (20 IU) intranasally
DRUGPlacebo
Administration of placebo intranasally
Sponsors
University of Electronic Science and Technology of China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design
Eligibility
Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy participants * Non smokers
Exclusion criteria
* Previous or current medical, psychiatric, neurological disorder * Regular medication * Use of any psychoactive substances in the 24 hours before experiment * Contra-indications for vasopressin * Contra-indications for eye-tracking data acquisition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of vasopressin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli | 45 minutes - 100 minutes after treatment | Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions |
| Effect of vasopressin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli | 45 minutes - 100 minutes after treatment | Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Emotion-specific effects of vasopressin administration on saccade/antisaccade latencies towards the separate facial emotions | 45 minutes - 100 minutes after treatment | Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions |
| Emotion-specific effects of vasopressin administration on saccade/antisaccade error rates for the separate facial emotions | 45 minutes - 100 minutes after treatment | Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin and placebo treatment conditions |
Countries
China
Outcome results
None listed